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Background: Vorapaxar reduces the risk of cardiovascular death (CVD), myocardial infarction (MI), and stroke in stable patients (pts) with 
prior atherothrombosis. The role of vorapaxar in pts with severe CAD who undergo CABG and the safety with respect to bleeding are of 
strong interest for clinical practice.
methods: TRA 2P-TIMI 50 was a randomized, double-blinded, placebo-controlled trial of vorapaxar in 26,449 pts with stable 
atherosclerosis followed for 30 mo (median). To address 2 issues, we 1) investigated the efficacy of vorapaxar among pts with a history 
of CABG prior to randomization (n=2,942) and 2) assessed the safety among 319 pts receiving study drug who underwent a new CABG 
during the trial. Consistent with labeling pts with prior stroke/TIA were excluded.
results: Pts with prior CABG were at higher risk for CVD, MI, or stroke when compared to pts without prior CABG (13.7% vs. 7.8%, 
p<0.001). Among pts with prior CABG, vorapaxar significantly reduced the risk of CVD, MI, or stroke (Table-A, 11.9% vs. 15.6%, HR 0.71, 
95% CI 0.58-0.88, p=0.001; number-needed-to-treat = 27). In pts undergoing CABG while receiving vorapaxar, the rate of TIMI CABG 
major bleeding within 30 days of surgery was 6.0% vs. 4.2% with placebo (Table-B, HR 1.43, 95% CI 0.53-3.84, p=0.48).
Conclusion:  In pts with prior CABG, vorapaxar significantly reduced the risk of recurrent major CV events. In pts undergoing CABG while 
receiving vorapaxar, the bleeding risk appeared similar to that seen in the overall trial population.
A) Efficacy and Safety of Vorapaxar in Patients with Prior CABG (n = 2,942)
Vorapaxar Placebo
Outcome Event Rate Event Rate Hazard Ratio (95% CI) p Value
CV death, MI, or stroke 11.9% 15.6% 0.71 (0.58-0.88) 0.001
CV death 4.2% 5.0% 0.83 (0.58-1.20) 0.32
MI 8.0% 10.8% 0.68 (0.52-0.88) 0.003
Stroke 1.3% 1.7% 0.79 (0.42-1.50) 0.47
GUSTO Moderate/Severe Bleeding 6.8% 3.7% 1.87 (1.28-2.72) 0.001
B) Efficacy and Safety of Vorapaxar in Patients Undergoing CABG During the Trial (n= 319)
Vorapaxar Placebo
Outcome Event Rate Event Rate Hazard Ratio (95% CI) p Value
CV death, MI, or stroke within 30 days of CABG 3.3% 4.8% 0.54 (0.18-1.65) 0.28
TIMI CABG Major Bleeding within 30 days of CABG 6.0% 4.2% 1.43 (0.53-3.84) 0.48
